MedTrace Logo

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

NCT01367314 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2011-06-07

No results posted yet for this study

Summary

This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.

Conditions

  • Impetigo

Interventions

DRUG

NVC-422

Dermal Gel applied 3 times per day for 7 days

Sponsors & Collaborators

  • Novum Pharmaceutical Research Services

    collaborator INDUSTRY

  • International Dermatology Research, Inc.

    collaborator OTHER

  • NovaBay Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Kenneth D. Krantz, MD, PhD · NovaBay Pharmaceuticals, Inc.

  • Daisy M. Blanco, MD · Instituto Dermatológico

  • Jesús Feris-Iglesias, MD · Hospital Infantil Dr. Robert Reid Cabral

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-05-31
Completion
2010-12-31

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367314 on ClinicalTrials.gov